PwC put a number on the menopause market: $10 billion to $15 billion today, growing to $15 billion to $25 billion by 2030. That figure has become the benchmark that investors, founders, and employers reach for when sizing the opportunity. But there’s a problem with it.
Claire Love, the PwC Deals Strategy Principal who built the analysis, told me the number deliberately excludes three of menopause’s largest downstream consequences. Osteoporosis, cardiovascular disease, and genitourinary syndrome are not included.
The $10–15 billion measures the menopause transition. It does not measure what menopause does to a woman’s body over the 30-plus years that follow. That is a different market—one that has no coordinated name or investment behind it…yet.
What The $15 Billion Figure Leaves Out
Love did not minimize the omission. “Bone loss is just a massive, massive dynamic within menopause,” she said, adding a personal note: She has fractured her hip twice and has osteopenia. But the methodological choice to exclude downstream conditions was deliberate. PwC drew a narrow boundary to avoid overlapping with existing disease-category market sizings. Defensible as a methodology. But it means the published number is a floor, not a ceiling.
Three conditions sit just outside that boundary, each substantial:
Osteoporosis: Women account for approximately 80% of cases, with estrogen decline at menopause as the primary driver. Existing treatments carry their own black box warnings and constrained treatment durations. Consumer devices designed to stimulate bone creation are just entering the market—a gap that signals unmet need, not a solved problem.
Cardiovascular disease: Premature menopause increases long-term heart risk by 40%, according to a March 2026 study from the Northwestern Feinberg School of Medicine. Love called the cardiovascular story “more nuanced,” but insufficient research targeted specifically at women remains the constraint, not the absence of a market.
Cognitive decline: Researcher Lisa Mosconi’s neuroscience work has established a link between estrogen decline and the trajectory of Alzheimer’s risk. The space is drawing investment, Love noted, but as a general neurology category, not as a post-menopause women’s health category.
Joanna Strober is the founder and CEO of Midi Health, the first menopause unicorn. She frames the clinical logic directly. “The things that we can give you in your 40s should make a huge impact in your 70s,” she says. Midi is already treating bone loss, cardiovascular protection, and cognitive health as part of its clinical scope, acting on emerging research while the investment categories that fund those conditions haven’t yet made the connection.
Reimbursement Is The Wrong Diagnosis
The menopause access problem is routinely described as a coverage failure. Insurers won’t pay. Women can’t afford it. Advocates push for mandated legislation. That framing is wrong, Love argues in this category.
“I actually think some of the reimbursement questions are a bit of a red herring,” she said. Most payers already cover hormone replacement therapy. The data point that reframes the argument is surprising. “Only 67% of women used insurance to cover their menopause prescriptions,” Love said. The 33% paying out of pocket frequently do so by choice. Generic HRT is inexpensive; routing it through insurance takes longer than writing the check.
The actual bottleneck is training. Fewer than 30% of internal medicine and family medicine residents actually receive menopause education, Love said. She added that only one in three OB/GYNs had a formal menopause curriculum. Melinda French Gates cited the same finding in her New York Times op-ed in June: less than a third of American OB/GYN residency programs offer a menopause curriculum of any kind.
Women are seeking care from specialized platforms precisely because their own physicians are underprepared. Love described the awareness-to-diagnosis gap as where the unrealized market value actually sits. “It’s more awareness, diagnosis, and treatment as the fundamental side of the patient journey,” she said. Platforms that solve upstream—getting women and their doctors to recognize the condition and the options—have more runway than those focused solely on treatment delivery.
Why This Market Has Room For Many Winners
Last month, I wrote about the funding gap between Midi Health ($250 million raised, unicorn valuation, 500 providers across all 50 states) and Alloy Women’s Health ($21 million raised, lean-by-design). The temptation is to read those two companies as competing bets on the same market. Love sees it differently.
“I don’t think this will consolidate down to just Midi,” she said. “I think…multiple models can win.”
The identified three coexisting opportunities. First, virtual-first platforms are growing as women act independently of their physicians.
Alloy co-CEO Monica Molenaar put the capital discipline case plainly. “We just need to always have the agency to not rely on anyone for anything. Frankly, women learn that, right?” Colleen Foster, general partner at Amboy Street Ventures and an Alloy investor, called it a structural pattern, “a generation of exceptionally disciplined founders who have learned to build meaningful businesses with far less capital than their peers.” Both models are rational. Neither is wrong.
Second, PE-backed OB/GYN practices are building menopause offerings—Love noted an important business dynamic: those practices are built around the childbearing years, but women stop coming in as they age into menopause, losing their patient base precisely as care complexity increases. Menopause is a patient retention play, not just a new category. And third, primary care is entering at scale, bringing an entirely different infrastructure and patient relationship to the category.
The Investment Case Hiding In Plain Sight
The menopause market is not a $15 billion opportunity. It is a $15 billion floor with an undefined ceiling, being undersized by the same conservative methodology that makes the number credible in the first place.
- The philanthropic-to-commercial pipeline is moving. Melinda French Gates announced $215 million in new philanthropic funding for women’s health through Pivotal—with menopause and midlife care named as a priority for the first time—bringing her two-year total commitment to more than $600 million.
- Twenty-five percent of U.S. employers now offer dedicated menopause benefits, up from 4% in 2023.
- Approximately $1.7 billion in private capital was deployed into menopause specifically between 2020 and 2025, growing at roughly 15% annually.
PwC’s next research report will focus on female-specific oncology. It will broaden the lens beyond breast cancer to all women’s cancers. The post-menopause investment market, with its cascade of underfunded downstream conditions, is a category the data is not yet equipped to fully measure. As Love said: “There is just tremendous opportunity here.”
The question investors should be asking is not how big the menopause market is. It is how much larger it becomes once someone counts the whole thing.